Abstract 469P
Background
The advancements in treatment strategies for cancer in Adolescent and Young Adults (AYAs) and early diagnosis has led to an increase in the cure rate and an increase in the number of AYA cancer survivors. The AYA patient is defined as an individual 15 to 39 years of age at the time of initial cancer diagnosis. AYA cancer survivors are at increased risk of developing various physical and psychosocial issues which vary from those in older adults. There are very few integrated survivorship programmes for AYA cancer survivors in India and this is a huge unmet need.
Methods
This online survey was directed at oncologists from various major specialties in India, with an interest in the care of AYA cancer patients and survivors. Oncologists practicing in India were sent the survey questionnaire through Google link via e-mail. Data was collected in SPSS and descriptive statistics were performed.
Results
We received 100 responses from June 2021 to September 2021 from oncologists all over India. 85% of respondents were medical oncologists, with 59% working at academic centers. Among oncologists who responded to this survey, 74% reported that AYA cancer survivors comprised ≤ 25% of their clinical practice. Major issues faced by most of the survivors included fatigue, anxiety, depression, fear of recurrence, and financial and social issues. Although 88% of the respondents reported the need for a separate follow-up clinic for AYA survivors, only 32% had a dedicated cancer survivor clinic or program at their center. Half of these oncologists had a team of multidisciplinary care providers in their clinic. 58% of the respondents reported that more than 50% of the survivors have resumed their normal life.
Conclusions
There is an unmet need for specialized care for AYA cancer survivors in India. Only 32% of oncologists have dedicated clinics for AYA cancer survivors. There is a need to develop survivorship programs for AYA survivors across the country.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
203P - Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jia He
Session: Poster Display
Resources:
Abstract
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract